The US market for interventional oncology devices continues to grow, driven by expanding treatable patient populations and increasing uptake of premium-priced technology. However, growth in this market will be hindered to some extent by mixed clinical data, which has somewhat deterred adoption of interventional oncology devices.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for interventional oncology devices in the US across a 10-year period.


The dynamic patient population eligible for interventional oncology procedures supports growth in the ablation device and embolization particle markets.

How have approved indications changed in recent years?

What are the fastest growing patient populations eligible for interventional oncology treatments?

What is the clinical evidence supporting the use of ablation or embolization particles in various types of cancer?

Microwave ablation devices and niche technologies, such as IRE, are rising in popularity among interventional oncologists.

What are the advantages and disadvantages of each type of ablation device?

How does the uptake of microwave ablation and IRE devices affect other types of ablation devices?

In which indications will these newer ablation devices experience the fastest adoption?

How can companies in the fragmented microwave ablation market gain a competitive advantage?

Growth in the premium-priced embolization particle segments, such as the DEBs and radioembolization sphere spaces, has slowed in recent years.

What factors has contributed to the slowing growth in these markets?

What are challenges facing physicians and competitors in this space?

How has M&A activity shaped the competitive embolization particles market in recent years?

Table of contents

  • United States
    • Abstract
    • Executive Summary
      • Market Highlights
      • Competitive Highlights
      • Market Developments
      • End-User Insights
      • Key Report Updates
      • Procedures Covered
      • Products Covered
    • Version History
    • Interventional Oncology Device Market
      • Market Highlights
      • Market Definitions
      • Market Forecast Data
      • Competitive Highlights
      • Market Shares
      • Competitive Factors and Strategies
        • Clinical Data
        • Reimbursement
        • Mergers, Acquisitions, and Partnerships
        • Product Improvements and Innovations
        • Product Portfolio Management
        • Physician Training and Marketing
      • Market Developments
    • Ablation Device Market
      • Market Highlights
      • Market Definitions
      • Market Forecast Data
        • Radiofrequency Ablation Devices
        • Microwave Ablation Devices
        • Cryoablation Devices
        • Irreversible Electroporation Ablation
      • Competitive Highlights
      • Market Shares
      • Competitive Factors and Strategies
        • Clinical Data
        • Product Improvements and Innovations
    • Embolization Particle Market
      • Market Highlights
      • Market Definitions
      • Market Forecast Data
        • PVA Particles
        • Microspheres
        • Drug-Eluting Beads
        • Radioembolization Spheres
      • Competitive Highlights
      • Market Shares
      • Competitive Factors and Strategies
        • Mergers, Acquisitions, and Partnerships
        • Product Portfolio Management
        • Physician Training and Marketing
    • Appendix
      • Abbreviations
      • Bibliography

Author(s): Michael Tian, PhD

Michael Tian is a senior analyst within the Cardiovascular Medtech Insights team at Decision Resources Group and is an expert in interventional cardiology, cardiac surgery, vascular access, and interventional oncology device markets. Michael spends much of his time exploring and translating large claims and hospital purchase datasets into intriguing stories within the global MedTech market, and he is always looking for the next challenging question to tackle. Michael holds a in Physiology and Neuroscience from the University of Toronto.


Related Reports

Interventional Oncology Devices | Medtech 360 | Market Insights | Asia Pacific

Despite pricing pressures and the release of mixed clinical data, the Asia Pacific interventional oncology device market will expand rapidly through 2027, driven by the continued growth of cance...

View Details

Interventional Oncology Devices | Medtech 360 | Market Insights | Europe

The European interventional oncology device market will be driven by moderate procedure volume growth, spurred by enhanced cancer detection, rising patient and physician awareness, improved reim...

View Details

Interventional Oncology Devices | Medtech 360 | Market Insights | Asia Pacific (Supplemental)

The Asia Pacific market for interventional oncology will expand through 2027, driven primarily by continued growth of cancer incidence, improving access to treat...

View Details

Interventional Oncology Devices | Medtech 360 | Market Insights | Europe (Supplemental)

The European interventional oncology device market will be characterized by procedure volume growth, spurred by enhanced reimbursement, product improvements, and the availability of new technolo...

View Details